Despite this setback, Sun Pharma’s stock has rallied 43 per cent year-to-date, fueled by growth in speciality drugs, emerging markets, and domestic sales.

Sun Pharma faces a delay in the U.S. launch of its drug Leqselvi due to a preliminary injunction by the New Jersey court, pending further legal proceedings or patent expiration in December 2026. The company plans to appeal the decision while considering a potential settlement with Incyte.